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Introduction
Phytanic acid [3R,S,7R,11R-(3,7,11,15-tetramethyl)hexadecanoic
acid] is a dietary fatty acid, particularly abundant in foods such as red
meat and dairy products.1 Phytanic acid is metabolised by α-oxidation
in the body to produce a mixture of 2R- and 2S-methyl pristanic acid
[2R,S,6R,10R-(2,6,10,14-tetramethyl)pentadecanoic acid] epimers.2
The acyl-CoA oxidases responsible for the further metabolism of
pristanoyl-CoA by β-oxidation have the absolute requirement for the
2S-methyl configuration.3 The enzyme involved in the conversion of
the 2R to the 2S isomer is α-methylacyl-CoA racemase (AMACR).4
AMACR levels are increased (up to 9-fold) in all types of prostate
cancers and phytanic acid has been shown to have a role in
regulating levels.5 It was demonstrated that reducing AMACR levels
using siRNA reduced the proliferation of prostate cancer cells, making
AMACR an attractive target.6
A recently developed colorimetric assay uses a reaction, in which a
colourless acyl-CoA substrate is converted into a yellow product by
AMACR (Scheme 1). The formation of the yellow product allows the
activity of the AMACR to be assayed in 96-well plates allowing
simultaneous analysis of many samples (unpublished work, paper in
preparation).
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Scheme 1: The novel E1cB reaction catalysed by AMACR. The
colourless CoA substrate is converted to a yellow 2,4-
dinitrophenolate product and a colourless acyl-CoA product in a
single-step irreversible reaction.
Project Aims
Currently, all the rationally designed AMACR inhibitors are acyl-CoA
analogues because the CoA moiety is essential for binding. However,
acyl-CoA inhibitors are not drug-like due to having high MW and a
zwitterionic charge. The aim of this project was to discover small
molecule inhibitors of AMACR by performing high-throughput
screening of library containing 7680 drug-like compounds.
Methods
High throughput screening was performed in 96-well half area plates
in 100μL total volume. The activity of the enzyme was assayed by
measuring the absorbance at 354 nm and 390 nm. The final
concentration of library compounds, substrate and enzyme were 30
µM, 18 µM and 0.087 mg.mL-1.
Figure 1: High-throughput screening of library compounds.  
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IC50 Determination
IC50 values for some known AMACR inhibitors, such as R- and S-
Ibuprofenoyl-CoA, ranged between 0.5 μM and 20 μM.7,8 IC50 values
for the new compounds were determined (Figure 3), which were in the
same range. This suggests that the new compounds have a similar
potency to rationally designed inhibitors.
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Reversibility experiments
Reversibility experiments also suggest that the compounds identified
are reversible enzyme inhibitors as opposing to non-specific
denaturing agents (Figure 4). The mode of inhibition is reversible
because the activity of the enzyme is fully restored upon diluting the
30 μM inhibitor to 0.66 μM inhibitor.
Figure 3: IC50 curves for three selected inhibitors (drugs 1-3). The
determined IC50 values were: 15.2 μM (Drug 1) 9.3 μM (Drug 2) and
12.8 μM (Drug 3).
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Figure 4: Reversibility experiments three selected inhibitors (drugs 1-3).
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Figure 2: SDS-PAGE analysis of human AMACR 1A.
Results and Discussion
Human His-tagged enzyme was expressed in Rosetta2 (DE3) cells
and lysed using the One Shot cell disruption system. The enzyme was
purified by metal chelate chromatography and buffer exchanged in 10
mM NaH2PO4-NaOH, pH 7.4 (Figure 2).
High throughput screening
Compounds were screened using the assay and possible inhibitors
(‘hits’) were identified by comparing absorbance traces with those for
positive and negative controls, Approximately 70 ‘hits’ were identified,
giving a ‘hit’ rate of ~0.9%, which is consistent with the hit rate of <1%
expected from a diverse and unbiased library.
